Gut Microbiome and Multiple Sclerosis: New Insights and Perspective Publisher Pubmed



Esmaeil Amini M^{1, 2} ; Shomali N^{3, 4} ; Bakhshi A² ; Rezaei S⁵ ; Hemmatzadeh M^{3, 4} ; Hosseinzadeh R⁶ ; Eslami S⁷ ; Babaie F⁸ ; Aslani S⁶ ; Torkamandi S⁸ ; Mohammadi H^{9, 10} Show Affiliations
Source: International Immunopharmacology Published:2020

Abstract

The human gastrointestinal microbiota, also known as the gut microbiota living in the human gastrointestinal tract, has been shown to have a significant impact on several human disorders including rheumatoid arthritis, diabetes, obesity, and multiple sclerosis (MS). MS is an inflammatory disease characterized by the destruction of the spinal cord and nerve cells in the brain due to an attack of immune cells, causing a wide range of harmful symptoms related to inflammation in the central nervous system (CNS). Despite extensive studies on MS that have shown that many external and genetic factors are involved in its pathogenesis, the exact role of external factors in the pathophysiology of MS is still unclear. Recent studies on MS and experimental autoimmune encephalomyelitis (EAE), an animal model of encephalitis, have shown that intestinal microbiota may play a key role in the pathogenesis of MS. Therefore, modification of the intestinal microbiome could be a promising strategy for the future treatment of MS. In this study, the characteristics of intestinal microbiota, the relationship between intestine and brain despite the blood-brain barrier, various factors involved in intestinal microbiota modification, changes in intestinal microbial composition in MS, intestinal microbiome modification strategies, and possible use of intestinal microbiome and factors affecting it have been discussed. © 2020 Elsevier B.V.